The ability of Tβ4 to induce mtROS is reminiscent of the activity of pioglitazone, a peroxisome proliferator–activated receptor γ (PPARγ) agonist, currently approved for the treatment of diabetes mellitus type 2 and recently proposed as a therapeutic molecule for CGD (Migliavacca et al, 2016). Here, PPARG is linked to chronic granulomatous disease.